Drug Profile
Minocycline controlled-release - OraPharma
Alternative Names: Arestin; Arestin LCM; Minocycline microspheresLatest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Wyeth
- Developer OraPharma; Wyeth
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Periodontitis
- Discontinued Peri-implantitis
Most Recent Events
- 09 Aug 2016 Discontinued - Phase-III for Peri-implantitis in United Kingdom, Sweden, Germany and USA (Subgingival) based on analysis of a phase III study data (Valeant Pharmaceuticals Form10-Q, August 2016)
- 24 Jun 2014 OraPharma completes a phase III trial in Peri-implantitis in USA, United Kingdom, Germany & Sweden (NCT01539564)
- 14 Jun 2014 Phase-III clinical trials in Peri-implantitis in United Kingdom & Sweden (Subgingival)